Engineered immune cells take on Hard-to-Treat cancers in early trial
NCT ID NCT05003895
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This Phase 1 trial tests a new treatment for people with advanced solid tumors that express a protein called GPC3, including liver cancer. The treatment uses the patient's own T cells, which are modified in a lab to better recognize and attack cancer cells. Participants receive chemotherapy followed by a single infusion of these modified cells. The main goal is to see if the treatment is safe and feasible, with a small group of 38 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-GPC3 CAR-T cells (a personalized immune treatment made from the patient's own T cells, modified to target GPC3 on cancer cells)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced liver cancer or other GPC3-positive solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 38 participants, so the main goal is safety, not effectiveness. The treatment may not shrink tumors, and there are risks from chemotherapy and the CAR-T cells themselves, such as severe immune reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.